ASSESSMENT OF COENZYME-Q10 TOLERABILITY IN HUNTINGTONS-DISEASE

We performed a 6-month open-label trial to evaluate the tolerability a nd efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's dis ease (HD). Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (H DFCS), and standardized neuropsychological measures. Adverse events (A Es) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, altho ugh four subjects reported mild AEs, including headache, heartburn, fa tigue, and increased involuntary movements. There was no significant e ffect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in long-ter m clinical trials designed to slow the progression of HD.